Results 251 to 260 of about 204,414 (356)

A complex response element in intron 1 of the androgen-regulated 20-kDa protein gene displays cell type-dependent androgen receptor specificity

, 1993

openalex   +2 more sources

Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background As prostate cancer (PCa) remains one of the leading causes of cancer‐related death in men, it is important to develop effective therapeutic approaches for the treatment of metastatic PCa and to improve the accuracy of prognosis for aggressive tumors.
Anna‐Lena Lemster, Sarah Grünhagen, Sarah Schmalfeld, Florian Lenz, Anna Natzius, Anne Offermann, Sven Perner, Jiong Zhang, Verena Sailer, Jutta Kirfel   +9 more
wiley   +1 more source

Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance. [PDF]

Front Oncol
Li C, Cheng D, Li P.
europepmc   +1 more source

Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study

The Prostate, EarlyView.
ABSTRACT Background Prostate cancer (PCa) is the second most common solid tumor in men, and its incidence is strongly dependent on age. With the aging global population, this poses a significant medical and sociodemographic issue. As treatment options for castration‐resistant prostate cancer (CRPC) expand, the proportion of elderly patients with CRPC ...
Takafumi Fukushima, Keisuke Goto, Yoshinori Nakano, Shinsaku Tasaka, Kyohsuke Iwane, Ryo Tasaka, Kohei Kobatake, Akihiro Goriki, Asuka Toshida, Akiko Abe, Misako Ishihara, Hikaru Nakahara, Masanori Motonaga, Kentaro Tokumo, Yasutoshi Fujii, Hayes Clair Nelson, Hiroaki Niitsu, Shinya Ohara, Yuji Urabe, Wataru Okamoto, Eiso Hiyama, Koji Arihiro, Takao Hinoi, Nobuyuki Hinata   +23 more
wiley   +1 more source

PGC1α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers. [PDF]

Am J Cancer Res
Teramoto Y, Yang Z, Matsukawa T, Najafi MAE, Goto T, Miyamoto H.   +5 more
europepmc   +1 more source

Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) have significantly improved clinical outcomes for patients with metastatic prostate cancer (PC) but acquired ARPI resistance remains universal. Maximizing ARPI treatment duration is crucial to optimal clinical outcomes, but current clinical tools to detect acquired ARPI resistance ...
Marina Nasrin Sharifi, Erika Heninger, Matthew Leeson Bootsma, Emma Elizabeth Recchia, Matthew Thomas Breneman, Amy Kristine Taylor, Shuang George Zhao, Aaron Matthew LeBeau, David Kosoff   +8 more
wiley   +1 more source

Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone. [PDF]

Breast Cancer Res
Ingle JN, Suman VJ, Solanki MH, Passow MR, Campbell JD, Wang L, Goetz MP.   +6 more
europepmc   +1 more source

Late Bowel Symptoms in Long‐Term Survivors of Prostate Cancer Following Radiotherapy

The Prostate, EarlyView.
ABSTRACT Background Despite advances in radiotherapy planning, some long‐term prostate cancer survivors experience persistent symptoms. Although overall quality of life appears comparable between patients treated with definitive and salvage radiotherapy and aligns with normative data, prostate‐specific deficits—particularly bowel symptoms—may persist ...
Isabella Gruber, Oliver Koelbl, Maria M. Meier   +2 more
wiley   +1 more source

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. [PDF]

Future Oncol
Chi KN, McKay RR, Sandhu S, Arranz JA, Barthélémy P, Hadaschik B, Matsubara N, Shore ND, Ye D, Cascella T, Irincheeva I, Kreiser S, Thiery-Vuillemin A, Rathkopf DE.   +13 more
europepmc   +1 more source

Annexin A1‐Targeted d‐Peptide‐Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background N‐terminus 15 amino acid (MC16) of Annexin A1 (ANXA1) is an effective therapeutic target for tumors and tumor vasculature as it specifically localizes to the cell surface of tumor cells and tumor vascular endothelial cells. We identified the d‐type peptide (hpnevrs, dhp7) by mirror‐image phage display targeting l‐type MC16 and ...
Kai Ozaki, Tohru Yoneyama, Yuka Kubota, Mihoko Sutoh Yoneyama, Motohiro Nonaka, Tomonori Suzuki, Ryuma Tanaka, Chikara Ohyama, Shingo Hatakeyama   +8 more
wiley   +1 more source